The current study is a comprehensive molecular profiling of plasma and whole-blood RNA samples collected from two cohorts of biologic-naïve RA patients from the Corrona CERTAIN registry [20] immediately prior to initiation of anti-TNF treatment (baseline; BL) and following 3 months of therapy (MO3). The gene discussed is TNF; the disease is rheumatoid arthritis.